EUVIMEDEUVIMED entdecken
ÄquivalenzstudieRandomisierte kontrollierte Studie

Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial

Pablo Garcia-Manau, Erika Bonacina, Raquel Martin-Alonso, Lourdes Martin, Ana Palacios, Maria Luisa Sanchez-Camps, Cristina Lesmes, Ivan Hurtado, Esther Perez, Albert Tubau, Patricia Ibañez, Marina Alcoz und 30 weitere

Nature Medicine · 2025

DOI: 10.1038/s41591-024-03421-9 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Nature Medicine, 2025. Verfasst von Pablo Garcia-Manau und 41 weiteren Autor:innen. Beteiligte Einrichtung: Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública, Universitat Autònoma de Barcelona, Bellaterra, Spain. Hauptthemen laut MEDLINE: Angiogenesis Inducing Agents, Fetal Growth Retardation, Placenta Growth Factor, Ultrasonography, Doppler. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small fetuses, with estimated fetal weight (EFW) below the tenth percentile, are classified as fetal growth restriction (FGR) or small for gestational age (SGA) based on prenatal ultrasound. FGR fetuses have a greater risk of stillbirth and perinatal complications and may benefit from serial ultrasound scans to guide early delivery. Abnormal serum angiogenic factors, such as the soluble fms-like tyrosine kinase-1 (sFlt-1):placental growth factor (PlGF) ratio, have shown potential to more accurately distinguish FGR from SGA, with fewer false positives. This randomized controlled trial compared a management protocol based on the sFlt-1:PlGF with EFW and Doppler ultrasound in avoiding adverse perinatal outcomes in small fetuses after 36 weeks of gestation. A total of 1,088 pregnant women with singleton pregnancies were randomized to either the Doppler-based (control) or the sFlt-1:PlGF-based (intervention) protocol. The primary outcome, neonatal acidosis or Cesarean delivery as a result of abnormal cardiotocography, was assessed in 1,013 participants. The incidence was 10.5% in the intervention group and 10.0% in the control group (absolute difference, 0.53 (-3.21 to 4.26)), with the upper limit of the confidence interval

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis Inducing AgentsFetal Growth RetardationPlacenta Growth FactorUltrasonography, DopplerUltrasonography, PrenatalVascular Endothelial Growth Factor Receptor-1AdultFemaleHumansInfant, NewbornPregnancyFetal WeightGestational AgeInfant, Small for Gestational Age

Substanzen

Angiogenesis Inducing AgentsFLT1 protein, humanPGF protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1

Autor:innen und Institutionen

  • Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Department of Obstetrics, Hospital Universitario de Torrejón, Madrid, Spain.
  • School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
  • Department of Obstetrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
  • Department of Obstetrics, Hospital General Universitari Dr. Balmis, Alicante, Spain.

Zitieren

APA

Garcia-Manau, P., Bonacina, E., Martin-Alonso, R., Martin, L., Palacios, A., Sanchez-Camps, M. L., Lesmes, C., Hurtado, I., Perez, E., Tubau, A., Ibañez, P., Alcoz, M., Valiño, N., Moreno, E., Borrero, C., Garcia, E., Lopez-Quesada, E., Diaz, S., Broullon, J. R., …, & Mendoza, M. (2025). Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03421-9

Vancouver

Garcia-Manau P, Bonacina E, Martin-Alonso R, Martin L, Palacios A, Sanchez-Camps ML, et al. Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial. Nature Medicine. 2025. doi:10.1038/s41591-024-03421-9

BibTeX
@article{GarciaManau2025,
  author = {Garcia-Manau, Pablo and Bonacina, Erika and Martin-Alonso, Raquel and Martin, Lourdes and Palacios, Ana and Sanchez-Camps, Maria Luisa and Lesmes, Cristina and Hurtado, Ivan and Perez, Esther and Tubau, Albert and Ibañez, Patricia and Alcoz, Marina and Valiño, Nuria and Moreno, Elena and Borrero, Carlota and Garcia, Esperanza and Lopez-Quesada, Eva and Diaz, Sonia and Broullon, Jose Roman and Teixidor, Mireia and Chulilla, Carolina and Ferrer-Costa, Roser and Gil, Maria M and Lopez, Monica and Ramos-Forner, Gemma M and Blanco, José Eliseo and Moreno, Anna and Lázaro-Rodríguez, Marta and Vaquerizo, Oscar and Soriano, Beatriz and Fabre, Marta and Gomez-Valencia, Elena and Cuiña, Ana and Alayon, Nicolas and Sainz-Bueno, Jose Antonio and Vives, Angels and Esteve, Esther and Ocaña, Vanesa and López, Miguel Ángel and Maroto, Anna and Carreras, Elena and Mendoza, Manel},
  title = {Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial},
  journal = {Nature Medicine},
  year = {2025},
  doi = {10.1038/s41591-024-03421-9}
}
Kostenlos starten →